secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0000950170-23-056122
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne reports Q3 net loss $60.2M, cash $157.8M; clinical data due Jan 2024
-------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $157.8M; funding expected through 2024.
- Net loss of $60.2M ($0.99 per share) vs. $41.4M ($0.80) in Q3 2022; R&D expenses rose to $55.3M from $34.7M.
- ACHIEVE trial (DYNE-101 in DM1) fully enrolled through 3.4 mg/kg; dose escalation to 6.8 mg/kg enrolling; over 150 doses, no anemia or discontinuations.
- DELIVER trial (DYNE-251 in DMD) fully enrolled through 10 mg/kg; dose escalation to 20 mg/kg enrolling; over 175 doses, no anemia or discontinuations.
- Initial safety, splicing, dystrophin and functional data from both trials expected around J.P. Morgan Healthcare Conference in early January 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/0000950170-23-056122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/dyn-20231030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer